Currently out of the existing stock ratings of Daniil Gataulin, 81 are a BUY (85.26%), 14 are a HOLD (14.74%).

Daniil Gataulin

Work Performance Price Targets & Ratings Chart

Analyst Daniil Gataulin, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 27.81% that have a potential upside of 42.97% achieved within 183 days.

Daniil Gataulin’s has documented 165 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on OCUL, Ocular Therapeutix at 18-Feb-2026.

Wall Street Analyst Daniil Gataulin

Analyst best performing recommendations are on QURE (UNIQURE NV).
The best stock recommendation documented was for QURE (UNIQURE NV) at 9/8/2025. The price target of $35 was fulfilled within 16 days with a profit of $17.57 (100.8%) receiving and performance score of 63.

Average potential price target upside

of $23.21 (180.2%) on QURE (UNIQURE NV).
of $13.78 (63.11%) on OTLK (OUTLOOK THERAPEUTICS INC).
of $12.66 (158.96%) on EYPT (EYEPOINT PHARMACEUTICALS).

ADVM Adverum Biotechnologies AGTC Applied Genetic KOD Kodiak Sciences OCGN Ocugen OYST Oyster Point Pharma RGNX Regenxbio EYPT Eyepoint Pharmaceuticals FREQ Frequency Therapeutics OTLK OUTLOOK THERAPEUTICS INC FBRX Forte Biosciences CGTX Cognition Therapeutics CRVO CervoMed OCS Oculis Holding AG Ordinary shares CLSD Clearside Biomedical MGTX MeiraGTx Holdings PLC OCUL Ocular Therapeutix QURE Uniqure NV

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matthew Caufield (HC WAINWRIGHT)